MaaT Pharma Extends Cash Runway as Regulatory Setbacks Reshape…

Event summary

MaaT Pharma's cash runway extended to December 2026 through cost-cutting measures and financing efforts.
EMA maintained negative opinion on MaaT013 (Xervyteg®) conditional marketing authorization application despite re-examination.
Company plans PHOENIX Phase 3 trial for MaaT013, subject to funding and regulatory clearance.
Operating loss widened to €18.3 million in H1 2026 from €15.1 million in H1 2025, driven by R&D expenses.
Revenue decreased 55% to €1.1 million due to changes in Early Access Program revenue model.

The big picture

MaaT Pharma faces significant regulatory hurdles following the EMA's rejection of its lead candidate, MaaT013. The company is pivoting to a Phase 3 trial while managing cash constraints and exploring financing options. This strategic shift comes amid broader industry challenges in bringing microbiome-based therapies to market, highlighting the need for robust clinical evidence and regulatory flexibility. The company's ability to execute on its revised plans will be critical in determining its long-term viability in the competitive oncology space.

What we're watching

Regulatory Pathway: Whether MaaT Pharma can successfully navigate the PHOENIX trial to secure future approvals for MaaT013.
Funding Strategy: The pace at which MaaT Pharma can secure additional financing to support its priority programs.
Pipeline Progress: How the strategic review of assets will impact the development timelines for MaaT033 and MaaT034.